KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Shares Outstanding (2016 - 2024)

Historic Shares Outstanding for Arbutus Biopharma (ABUS) over the last 16 years, with Q4 2024 value amounting to $190.0 million.

  • Arbutus Biopharma's Shares Outstanding rose 1183.04% to $190.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $190.0 million, marking a year-over-year increase of 1183.04%. This contributed to the annual value of $190.0 million for FY2024, which is 1183.04% up from last year.
  • Per Arbutus Biopharma's latest filing, its Shares Outstanding stood at $190.0 million for Q4 2024, which was up 1183.04% from $169.9 million recorded in Q4 2023.
  • Arbutus Biopharma's 5-year Shares Outstanding high stood at $190.0 million for Q4 2024, and its period low was $69.0 million during Q1 2020.
  • In the last 5 years, Arbutus Biopharma's Shares Outstanding had a median value of $145.0 million in 2021 and averaged $126.4 million.
  • As far as peak fluctuations go, Arbutus Biopharma's Shares Outstanding surged by 6167.46% in 2021, and later surged by 788.29% in 2023.
  • Over the past 5 years, Arbutus Biopharma's Shares Outstanding (Quarter) stood at $89.7 million in 2020, then skyrocketed by 61.67% to $145.0 million in 2021, then rose by 8.6% to $157.5 million in 2022, then rose by 7.88% to $169.9 million in 2023, then grew by 11.83% to $190.0 million in 2024.
  • Its Shares Outstanding stands at $190.0 million for Q4 2024, versus $169.9 million for Q4 2023 and $165.1 million for Q1 2023.